RecruitingPhase 2NCT07167329

Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial

Studying Von Hippel-Lindau disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
José Claudio Casali da Rocha
Principal Investigator
José Claudio Casali da Rocha, Head of Oncogenetics
Intervention
Belzutifan(drug)
Enrollment
100 enrolled
Eligibility
14 years · All sexes
Timeline
20242026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07167329 on ClinicalTrials.gov

Other trials for Von Hippel-Lindau disease

Additional recruiting or active studies for the same condition.

See all trials for Von Hippel-Lindau disease

← Back to all trials